A Phase I, First-in-Human Study of SAR441236, a Tri-specific Broadly Neutralizing Antibody, in Participants With HIV
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of SAR441236, a tri-specific broadly neutralizing antibody against the human immunodeficiency virus (HIV).
DURATION: April 2019 - Ongoing
STUDY TYPE: HIV Treatment
DESIGN: Randomized, parallel assigned, double masked interventional study